Drugs / Tumor Lysate Vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01678352 | Oct 2012 → Nov 2017 | grade II glioma | Frank Lieberman | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01400672 | Jul 2012 → Mar 2016 | diffuse intrinsic pontine glioma | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tumor Lysate Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01678352 ↗ |
| Modality | Vaccine | “Vaccine will be produced by the University Of Minnesota Molecular and Cellular Therapeutics Facility using the established brain tumor initiating cell (BTIC) cell line GBM-6 as...” NCT01400672 ↗ |